These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 9700544)

  • 41. [Antibiotic sensitivity tests of methicillin-resistant staphylococci].
    Sultan N; Türet S; Imir T
    Mikrobiyol Bul; 1991 Jul; 25(3):227-34. PubMed ID: 1762589
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Microbiological properties of teicoplanin.
    Greenwood D
    J Antimicrob Chemother; 1988 Jan; 21 Suppl A():1-13. PubMed ID: 2965119
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Sensitivity to antibiotics of 1042 strains of pathogenic staphylococci from healthy hospital personnel as disease carriers. Preliminary note].
    Lavillaureix J; Reeb E; Braun R; Mager ML
    Pathol Microbiol (Basel); 1969; 34(3):244-8. PubMed ID: 5379718
    [No Abstract]   [Full Text] [Related]  

  • 44. Antibiotic susceptibility patterns of Staphylococcus aureus and Staphylococcus epidermidis.
    Deng LJ; Luh KT; Hsieh WC; Ho SW
    Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi; 1981 Mar; 14(1):1-9. PubMed ID: 7261697
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Staphylococci in the hospital environment sensitivity to antibiotics].
    Ben Redjeb S; Ben Salah N; Bissardon O; Ennaifar M; Boujnah A
    Tunis Med; 1981; 59(4):307-9. PubMed ID: 7303174
    [No Abstract]   [Full Text] [Related]  

  • 46. Coagulase-negative staphylococci emerging during teicoplanin therapy and the determination of their sensitivity.
    Jones RN
    J Antimicrob Chemother; 1992 Jun; 29(6):725-7. PubMed ID: 1387134
    [No Abstract]   [Full Text] [Related]  

  • 47. Changing resistance to antimicrobial drugs, and resistance typing in clinically significant strains of Staphylococcus epidermidis.
    Richardson JF; Marples RR
    J Med Microbiol; 1982 Nov; 15(4):475-84. PubMed ID: 7175915
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [The invitro activity of teicoplanin and vancomycin against gram positive microorganisms (corrected)].
    Kayaokay Y; Hasçelik G; Gür D; Akalin E
    Mikrobiyol Bul; 1991 Oct; 25(4):321-5. PubMed ID: 1839050
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Oritavancin in vitro activity against gram-positive organisms from European and United States medical centers: results from the SENTRY Antimicrobial Surveillance Program for 2010-2014.
    Pfaller MA; Sader HS; Flamm RK; Castanheira M; Mendes RE
    Diagn Microbiol Infect Dis; 2018 Jun; 91(2):199-204. PubMed ID: 29567128
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Activity of dalbavancin against staphylococci and streptococci, assessed by BSAC and NCCLS agar dilution methods.
    Mushtaq S; Warner M; Johnson AP; Livermore DM
    J Antimicrob Chemother; 2004 Sep; 54(3):617-20. PubMed ID: 15321983
    [TBL] [Abstract][Full Text] [Related]  

  • 51. In vitro activity of telavancin and comparator antimicrobial agents against a panel of genetically defined staphylococci.
    Farrell DJ; Krause KM; Benton BM
    Diagn Microbiol Infect Dis; 2011 Mar; 69(3):275-9. PubMed ID: 21353951
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Multiply resistant staphylococci.
    Hale JH; Selkon JB
    Lancet; 1970 Sep; 2(7671):528-9. PubMed ID: 4194979
    [No Abstract]   [Full Text] [Related]  

  • 53. Does the use in animals of antimicrobial agents, including glycopeptide antibiotics, influence the efficacy of antimicrobial therapy in humans?
    Donnelly JP; Voss A; Witte W; Murray BE
    J Antimicrob Chemother; 1996 Feb; 37(2):389-92. PubMed ID: 8707753
    [No Abstract]   [Full Text] [Related]  

  • 54. Corrigendum to Twenty-Year Trends in Antimicrobial Susceptibilities Among
    Open Forum Infect Dis; 2019 May; 6(5):ofz202. PubMed ID: 31139676
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Correction: Antifungal susceptibilities of opportunistic filamentous fungal pathogens from the Asia and Western Pacific Region: data from the SENTRY Antifungal Surveillance Program (2011-2019).
    Pfaller MA; Carvalhaes CG; Rhomberg P; Messer SA; Castanheira M
    J Antibiot (Tokyo); 2022 Feb; 75(2):123. PubMed ID: 34408290
    [No Abstract]   [Full Text] [Related]  

  • 56. [What pharmaco-economic criteria should be considered when using glycopeptides].
    Zambrowski JJ
    Med Mal Infect; 2004 Jun; 34 Suppl 1():S103-5. PubMed ID: 15676223
    [No Abstract]   [Full Text] [Related]  

  • 57. Association of alterations in ParC and GyrA proteins with resistance of clinical isolates of Enterococcus faecium to nine different fluoroquinolones.
    Brisse S; Fluit AC; Wagner U; Heisig P; Milatovic D; Verhoef J; Scheuring S; Köhrer K; Schmitz FJ
    Antimicrob Agents Chemother; 1999 Oct; 43(10):2513-6. PubMed ID: 10508034
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Current susceptibilities of staphylococci to glycopeptides determined as part of an international resistance surveillance programme. Sentry Antimicrobial Surveillance Program.
    Jones ME; Jones RN; Sader H; Verhoef J; Acar J
    J Antimicrob Chemother; 1998 Jul; 42(1):119-21. PubMed ID: 9700544
    [No Abstract]   [Full Text] [Related]  

  • 59. Susceptibility of staphylococci to paldimycin, and emergence of resistance, in vitro.
    Chandrasekar PH; Sluchak JA
    J Antimicrob Chemother; 1989 Nov; 24(5):821-4. PubMed ID: 2600003
    [No Abstract]   [Full Text] [Related]  

  • 60. [Staphylococci and enterococci resistant to glycopeptides: the challenge of the year 2000?].
    Mainardi JL
    Pathol Biol (Paris); 1998 May; 46(5):289-90. PubMed ID: 9769886
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.